SCHEMBL5070038

SCHEMBL5070038

CCCCN(Cc1c(Cl)cccc1Cl)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CC

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 2/20 0.43
CRHR1 P34998 2/20 0.37
HDAC1 Q13547 1/20 0.36
C5AR1 P21730 1/20 0.36
ATP4A P20648 2/20 0.36
ATP4B P51164 2/20 0.36
TSHR P16473 3/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP3A4 P08684 2/20 0.35
HPGD P15428 2/20 0.35
HSD17B10 Q99714 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134964 0.93 P2RX7 (0.40) P2RX7CRHR1HDAC1ALDH1A1
SCHEMBL5135784 0.93 C5AR1 (0.38) P2RX7CRHR1HDAC1C5AR1ATP4A
SCHEMBL5134866 0.93 TSHR (0.42) P2RX7CRHR1HDAC1C5AR1ATP4A
SCHEMBL5136698 0.92 ALDH1A1 (0.39) P2RX7CRHR1HDAC1C5AR1TSHR
SCHEMBL5136494 0.89 P2RX7 (0.41) P2RX7CRHR1HDAC1C5AR1ATP4A
SCHEMBL5137113 0.89 TSHR (0.39) CRHR1C5AR1TSHRKDM4EALDH1A1
SCHEMBL5135270 0.87 KDM4E (0.39) P2RX7CRHR1HDAC1C5AR1ATP4A
SCHEMBL5072419 0.86 CRHR1 (0.36) P2RX7CRHR1C5AR1TSHRKDM4E
SCHEMBL5134752 0.86 C5AR1 (0.39) P2RX7CRHR1C5AR1TSHRKDM4E
SCHEMBL5136139 0.85 TSHR (0.37) CRHR1C5AR1TSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed